ESMO 2023 | Hepatitis B outcomes in KEYNOTE-966: HBV+ pts on pembrolizumab + gem/cis for advanced BTC

Stephen L. Chan, MBBS MRCP, FHKCP, FHKAM, FRCP, The Chinese University of Hong Kong, Hong Kong, China, discusses the safety of administering pembrolizumab plus gemcitabine and cisplatin in patients with hepatitis B being treated for biliary tract carcinoma in the Phase III KEYNOTE-966 (NCT04003636) trial. Dr Chan elaborates on the overall safety of these patients with the use of appropriate mitigative antivirals. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.